Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Immunity ; 2024 Jun 24.
Article in English | MEDLINE | ID: mdl-38955184

ABSTRACT

An important property of the host innate immune response during microbial infection is its ability to control the expression of antimicrobial effector proteins, but how this occurs post-transcriptionally is not well defined. Here, we describe a critical antibacterial role for the classic antiviral gene 2'-5'-oligoadenylate synthetase 1 (OAS1). Human OAS1 and its mouse ortholog, Oas1b, are induced by interferon-γ and protect against cytosolic bacterial pathogens such as Francisella novicida and Listeria monocytogenes in vitro and in vivo. Proteomic and transcriptomic analysis showed reduced IRF1 protein expression in OAS1-deficient cells. Mechanistically, OAS1 binds and localizes IRF1 mRNA to the rough endoplasmic reticulum (ER)-Golgi endomembranes, licensing effective translation of IRF1 mRNA without affecting its transcription or decay. OAS1-dependent translation of IRF1 leads to the enhanced expression of antibacterial effectors, such as GBPs, which restrict intracellular bacteria. These findings uncover a noncanonical function of OAS1 in antibacterial innate immunity.

2.
Commun Biol ; 4(1): 386, 2021 03 22.
Article in English | MEDLINE | ID: mdl-33753867

ABSTRACT

APOBEC3A (A3A) and APOBEC3B (A3B) enzymes drive APOBEC-mediated mutagenesis. Identification of factors affecting the activity of these enzymes could help modulate mutagenesis and associated clinical outcomes. Here, we show that canonical and alternatively spliced A3A and A3B isoforms produce corresponding mutagenic and non-mutagenic enzymes. Increased expression of the mutagenic A3B isoform predicted shorter progression-free survival in bladder cancer. We demonstrate that the production of mutagenic vs. non-mutagenic A3B protein isoforms was considerably affected by inclusion/skipping of exon 5 in A3B. Furthermore, exon 5 skipping, resulting in lower levels of mutagenic A3B enzyme, could be increased in vitro. Specifically, we showed the effects of treatment with an SF3B1 inhibitor affecting spliceosome interaction with a branch point site in intron 4, or with splice-switching oligonucleotides targeting exon 5 of A3B. Our results underscore the clinical role of A3B and implicate alternative splicing of A3B as a mechanism that could be targeted to restrict APOBEC-mediated mutagenesis.


Subject(s)
Alternative Splicing , Biomarkers, Tumor/genetics , Cytidine Deaminase/genetics , Minor Histocompatibility Antigens/genetics , Mutagenesis , Proteins/genetics , Urinary Bladder Neoplasms/genetics , Biomarkers, Tumor/metabolism , Cytidine Deaminase/metabolism , Epoxy Compounds/pharmacology , Exons , Gene Expression Regulation, Neoplastic , HEK293 Cells , HeLa Cells , Hep G2 Cells , Humans , Isoenzymes , Macrolides/pharmacology , Minor Histocompatibility Antigens/metabolism , Phosphoproteins/antagonists & inhibitors , Phosphoproteins/metabolism , Progression-Free Survival , Proteins/metabolism , RNA Splicing Factors/antagonists & inhibitors , RNA Splicing Factors/metabolism , Urinary Bladder Neoplasms/enzymology , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...